Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
Graphic element Addressed Diseases
- News
Graphic element Calls for proposals
  FP7 Calls
Graphic element Contact corner
  Scientific officers
  Subscribe to our mailing list
Framework programme: 5
Project number:
EC contribution: € 736 920
Duration: 36 months
Type: CA
Starting date: 1 February 2000
Graphic element Programme EVA (European Vaccine Against Aids) Centralised Facility For Aids Reagents
Keywords: AIDS; Vaccine; HIV; Reagents


  • To provide support for AIDS vaccine development through provision of key reagents.
  • Maintenance of repository of high quality, specialised research reagents.
  • To provide novel reagents to facilitate exploitation of new lines of vaccine research.
  • To promote multi-centre European AIDS vaccine research clusters such as EuroVac.
  • To support pre-clinical studies of candidate vaccines in animal models.
  • To support clinical studies of candidate vaccines in man.
  • Description:

    Programme EVA CFAR: An extensive and valuable inventory of over 1900 ‘state of the art’ reagents, most of which are not available commercially, has been built up at the CFAR repository at NIBSC.

    Provision of reagents: The provision of key reagents is a highly effective way of supporting and enhancing vaccine research and one where European added-value has true meaning and can be readily demonstrated. During the second year, over 4 900 reagents were distributed to 572 scientists, a 20% increase over year one.

    Pre-clinical research: High priority has continued to be given to the support of pre-clinical vaccine studies with the SIV-macaque model, through the provision of reagents and directed support for the European Network for Vaccine Evaluation in Primates (ENVEP).

    SHIV (HIV-SIV) chimaeras for vaccine challenge experiments: The development of SHIV chimaeric viruses carrying HIV envelopes from a range of strains has continued to be supported, so that HIV vaccines designed for man can be evaluated in the macaque model.

    DNA vaccines: Support has been provided for the development and production of a variety of DNA vaccines using different genes and expression systems to achieve a reproducible and durable immune response.

    Recombinant viral vectors: Programme EVA has supported the development of vaccines based on recombinant viral vectors such as the modified vaccinia Ankara and Semliki forest virus vectors, and has prepared batches of immunogens for collaborative vaccine studies.

    Immunological and virological reagents for vaccine studies: Reagents, such as recombinant proteins, peptides and viral isolates, are provided by EVA for a wide range of immunological and virological studies.

    Preparation of vaccines and reagents for use in clinical studies: As well as supporting preclinical evaluation of vaccine strategies, the programme is becoming increasingly involved in the support of clinical studies in man through the provision of key reagents. EuroVac is being provided with overlapping HIV-1 subtype C gag and nef peptides for analysing the cellular immune responses of vaccines.


    Harvey Holmes
    NIBSC, Blanche Lane
    South Mimms
    EN6 3QG Potters Ba
    United Kingdom
    Tel: +44 1707 654753
    Fax: +44 1707 649865


    1. H. Wigzell, Karolinska Institute, SE-Stockholm, Sweden
    2. A. Burny, Université Libre de Bruxelles, BE-Brussels, Belgium
    3. M. Esteban, Centro Nacional de Biotecnologia, ES-Madrid, Spain
    4. V. Erfle, GSF, DE-Neuherberg, Germany
    5. M. Girard, Centre de Recherche, Merieux-Pasteur Lyon, FR-Lyon, France
    6. J. Goudsmit, University of Amsterdam, NL-Amsterdam, The Netherlands
    7. G. Hunsmann, Deutsches Primatenzentrum (DPZ), DE-Goettingen, Germany
    8. K. Krohn, University of Tampere, FI-Tampere, Finland
    9. L Montagnier, Institute Pasteur, FR-Paris, France
    10. M. Papamichail, Helenic Anti-Cancer Institute, EL-Athens, Greece
    11. A. Siccardi, DIBIT, Istituto H San Rafaele, IT-Milan, Italy
    12. G. Schild, NIBSC, Potters Bar, Hertfordshire, United Kingdom

    Graphic element